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Hepatitis A remains a significant problem in travelers to developing nations. 
Immune serum immunoglobulin (ISIG), administered intramuscularly, is an 
effective form of prophylaxis but must be given every 5-6 months for 
extended stay or repeat travelers. Although the prevalence of immunity to 
hepatitis A in developed nations is relatively low, certain subgroups of the 
travel population may have a high enough prevalence of immunity to render 
screening a reasonable alternative to routine ISIG prophylaxis. Previous 
studies of British travelers have indicated that older patients, those of Asian 
descent, and those with a history of jaundice, may fulfill such criteria. Such 
criteria in U.S. travelers have not been studied. 
A retrospective study of patients at two U.S. university-affiliated travel 
clinics was performed to assess the value of certain indicators in past 
medical and travel history to predict immunity to hepatitis A. 762 patients 
above the age of 16 seen in either clinic were tested for hepatitis A antibody 
during 1987-1990. 112 immune subjects (15%) were identified. 61 immune 
individuals aged 18 to 81 and 121 non-immune individuals, aged 17-71, 
were studied. Of the 61 immune subjects, 48(79%) were over the age of 40, 
whereas 50(41%) of the non-immune subjects were over the age of 40 
(pc.0005) (odds ratio 5.2, 2.7-10.2, 95% Cl). Twenty-two (36%) of the 
immune individuals were bom outside of the U.S., whereas 14 (12%) of the 
non-immune individuals were born outside of the U.S. (pc.0005)(odds ratio 
4.3, 2.1-8.9, 95% Cl). Nineteen (31%) of the immune individuals gave a 
history of hepatitis whereas two (2%) of the non-immune individuals gave 
such a history (pc.0005)(odds ratio 26.2, 9.0-80.3, 95% Cl). Fifty-three 
(87%) of immune individuals gave a history of previous travel to developing 
nations whereas 75 (62%) of non-immune individuals gave such a history 
(pc.001)(odds ratio 4.1, 1.9-9.0, 95% Cl). Screening for immunity may be an 
appropriate alternative to routine ISIG prophylaxis in extended stay or 
repeat U.S. travelers if they are >40 years old, were born outside of the U.S., 




Hepatitis A is a significant complication of travel to the developing 
nations. A lower prevalence of immunity in the developed nations, 
combined with a higher incidence of disease and poorer sanitation 
measures in the developing nations renders unprotected travelers 
susceptible to contracting hepatitis A. Current Centers for Disease 
Control (CDC) recommendations call for passive immunization with 
pooled serum immunoglobulins(ISIG), which is an effective means of 
prophylaxis for these travelers. However, ISIG prophylaxis must be 
repeated every four to six months and is unnecessary and inconvenient 
for patients who have already developed a natural, active and lifelong 
immunity. Several studies performed in England have suggested that 
certain subpopulations of travelers to developing nations have a high 
enough prior probability of immunity to render serological testing a cost- 
effective screen. The purpose of this study was to search for factors in the 
past medical and travel history of patients at American travel clinics 
which might be associated with immunity. Determination of such factors 
might allow the clinician to use the patient interview to identify patients 
with a greater chance of immunity than that of the general population. 
Although this study is not designed to quantitatively assess the cost- 
effectiveness of serological testing in these patients, it provides the 
clinician with qualitative information that may enable him or her to spare 
the patient unnecessary ISIG injections. 
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In this introduction, the clinical importance of hepatitis A will first be 
reviewed, followed by a description of the risks posed to the U.S. travel 
clinic patient of contracting the disease. These risks are not well- 
quantified, and few studies even attempt to measure their magnitude. 
The effectiveness and safety of ISIG prophylaxis will then be addressed, 
as well as the importance of other considerations regarding its use. 
Finally, studies in England considering the prevalence of hepatitis A 
immunity in travel clinics and the costs of screening and prophylaxis will 
be reviewed, for their significance in the design of this study. 
Clinical Importance of Hepatitis A 
Epidemiology in General Population 
Hepatitis A is one of the less morbid hepatitides but is still of 
considerable clinical significance. 21,532 cases were reported to the CDC 
in 1983 and of the 7854 serologically confirmed cases, 33.2% were 
hospitalized and 0.6% died. In comparison, 1.6% of 8925 serologically 
confirmed cases of hepatitis B (24318 cases in total) ended in death and 
44.4% were hospitalized. 6.1% of the cases of hepatitis A reported in that 
year were attributed to international travel (1). 
Etiology 
The disease is caused by a 27 nanometer nonenveloped RNA 
picomavirus which is quite resistant to inactivation by physical and 
chemical means (2). Although the natural means of transmission of the 
virus is considered to be fecal-oral, parenteral inoculation is a successful 
method of inducing infection in experimental animals and in test 
subjects. Within one to two weeks after inoculation by either route, virus 
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is present in the liver, serum and stool (3). Fecal excretion and viremia 
generally disappear within days of the arrival of symptoms, at about four 
weeks after inoculation (4,5). Jaundice and elevations of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) appear at 
about this time, as well as anti-hepatitis A virus (HAV) IgM, as 
determined by enzyme-linked immunosorbent assay (ELISA)(6). The 
jaundice, elevated transaminases and symptoms are usually completely 
resolved by approximately three months after inoculation, whereas anti- 
HAV IgM persists in up to 30% of subjects (93% in one study) at six 
months after inoculation(7,8,9). Anti-HAV IgG appears at about four 
weeks after inoculation and probably persists for life, conferring active 
immunity on the subject(lO). 
Clinical Presentation 
The spectrum of presentation is quite varied. Fulminant hepatitis A is 
rare and is associated with jaundice, dark urine, abdominal pain and 
nausea(ll). As the prevalence of immunity in adult populations is much 
higher than the number of positive histories of jaundice or hepatitis 
would suggest, a large number of cases of hepatitis A must be 
asymptomatic. Hadler(12) found a rate of 84%, 50% and 20% of 
asymptomatic infections for day-care children aged 2, 3 to 4 and over 5 
years, respectively, while 11% of inoculated adult volunteers were found 
to be asymptomatic(13). A recent Chinese study of preschool children 
subjected to a common-source exposure to hepatitis A found that 25% of 
the children had an inapparent infection documented only by the 
presence of anti-HAV IgM or a change in anti-HAV IgG titers, while 50% 
of the children demonstrated a change in ALT and another 25% of the 
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children had clinical symptoms and jaundice. All children were found to 
be excreting HAV in their stools(14). Thus, both extremes of expression 
of hepatitis A are clinically significant for travelers. Hepatitis A can cause 
death, as well as cause a large number of asymptomatic infections. 
Furthermore, it is clear that a significant proportion of infected 
individuals may produce infectious stools without any overt signs of 
disease. 
Attempts to Assess and Control Risk to Unprophvlaxed U.S. 
Travelers of Contracting Hepatitis A During Travel to 
Developing Nations 
The risk of travelers from the developed countries contracting 
hepatitis A during travel to the developing nations depends on several 
factors, most of which have been poorly quantified. First, the prevalence 
of immunity among the travelers themselves must be considered, along 
with the incidence of infection in a given region of travel. The 
epidemiological pattern of infection in a given region, and putative 
explanations for this pattern may be even more important than reported 
incidences. The behavior of the travelers will determine the extent to 
which they expose themselves to the risks of infection posed by the 
environment and individuals in the region of travel. Finally, the efficiency 
of immunoprophylaxis, if given, must be considered. 
Prevalence of Immunitv/Susceptibilitv in the U.S. 
In the United States, a wide range of prevalences of anti-HAV IgG has 
been reported(15,16). Prevalence increases with increasing age and with 
decreasing socioeconomic status. Thus, for example, less than 10% of 
middle-class children tested in 1976 were HAV immune as compared to 
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nearly 75% of middle-class adults over 50 years old. Among poor, black 
populations in New York City, prevalence rose from 50% to over 75% in 
subjects aged 20 to over 50 years. Other factors have been suggested as 
playing a role as well. Foreign-bom individuals had an age-adjusted 
prevalence of 75% in these studies, as compared with 31% in American- 
born individuals. Middle-class whites with serological evidence of 
exposure to hepatitis B had a higher prevalence (54%) than those without 
such evidence (31%). In these studies, homosexuals did not have a higher 
prevalence. Furthermore, only 3-5% of HAV immune subjects gave a 
history of hepatitis! 15,16). 
These data suggest that, to the extent that a travel clinic population 
represents a cross-section of American society, a significant fraction of a 
travel clinic population would not be immune to hepatitis A, and would 
therefore be susceptible to contracting the disease during travel to 
developing nations. On the other hand, socioeconomic profiles of U.S. 
travel clinic populations in general, or the populations in this study are 
not available to confirm or refute the assumption that they represent a 
cross-section of U.S. society. However, since international travel is costly 
and since attendance at travel clinics usually requires self-payment by the 
patient, the socioeconomic status of our travel clinic population is 
probably higher than that of the general U.S. population. This would 
suggest that even a greater proportion of these travelers would be non- 
immune. 
In any case, these data demonstrate that there is no group in which the 
immune status of an individual could be a virtual certainty based on 
membership in that group. Furthermore, these studies were completed 

in the mid-1970's and prevalence among the younger age-groups might 
be substantially lower now. Indeed, the incidence of symptomatic 
hepatitis A is currently one case per 100,000 person-years, which would 
suggest that the prevalence of immunity among younger age-groups is 
now very low(17). Thus, in the absence of serological testing, the CDC 
recommends routine ISIG prophylaxis for all travelers to developing 
nations. How these prevalence data might render the serological testing 
of certain subgroups a reasonable alternative to ISIG prophylaxis, 
however, will be discussed later. 
Incidence and Prevalence of Hepatitis A in Developing 
Nations 
The true incidence of infection in the developing nations is also 
important in determining the risks for travelers of contracting hepatitis 
A. The lack of a carrier state and the short period of fecal shedding 
renders only currently infected individuals contagious either through 
personal contact or through contamination of food or water supplies. 
However, data on incidence is more difficult to collect than is data on 
prevalence. Furthermore, because hepatitis A is often an asymptomatic 
disease, reported incidence may give a misleading indication of how 
many people might actually be shedding virus at any one time. For 
example, a study in Israel demonstrated an increase in incidence of viral 
hepatitis from 0.8 to 1.2 cases per 1000 in the years 1951-1985 during 
which sanitary conditions had improved (18). An increase in the rate of 
reporting might explain these findings or, as the authors suggest, 
improved sanitary conditions may have caused the age of peak incidence 
to increase from the 1-4 year old age group to the 5-9 year old age group. 

when more infections are symptomatic. Thus, the number of people 
shedding virus might have decreased despite the apparent increase in 
incidence. A similar pattern was hypothesized for poliomyelitis following 
the sanitary improvements of the 20th century. On the other hand, an 
improvement in sanitary conditions of San Roma, Costa Rica was used to 
explain the drop in incidence of viral hepatitis in that city, from 253 to 
25 annual cases between the years 1973-1980(19). In neither of these 
two studies is serological type reported, which further emphasizes the 
difficulty in interpreting data such as these. 
Seroprevalence in very young populations could also be used as an 
indicator of the current, true incidence. A study of schoolchildren in 
Naples, Italy showed a decline in prevalence of anti-HAV IgG from 20.0% 
to 5.2% of seven-year olds between the years 1980 and 1988. These data 
came from different, albeit socioeconomically similar, districts and the 
change was attributed to improvement in sanitation(20). In contrast, in 
several small villages in the Andes, a prevalence of 86.9% was seen even 
in the 1-5 year-old age group, with no statistically significant differences 
between age groups, leading one to believe that hepatitis A continues to 
be hyperendemic in this region(21). 
Patterns of Infection in Developing Nations 
It is clear that quantitative assessments of infection rates in developing 
countries are rare and difficult to interpret. Thus, immunoprophylaxis is 
recommended for travel to all developing nations, and the classification 
of nations as "developing" is left ot the judgment of the clinician. Some 
greater discretion might be attained by classifying regions where 

hepatitis A is present in hyperendemic, endemic and epidemic form. For 
example, in the villages in the Andes, with a uniformly high prevalence 
rate in young children, hepatitis A is hyperendemic, signifying that 
exposure is universal by a very young age, presumably because sanitation 
is poor enough to allow continual common-vehicle transmission. Because 
of the young age at transmission, virtually all infections are asymptomatic. 
Apparently, although these populations would be expected to be small 
and isolated, the number of susceptibles is never exhausted. Otherwise, 
periodic re-introduction of the virus, with resulting epidemics and 
significant numbers of symptomatic cases would have to be postulated for 
such a high prevalence. In hyperendemic regions, a traveler would have a 
high risk of being exposed to HAV in drinking water, food and even 
personal contact. 
Endemic regions are those in which sanitation has improved enough so 
that common-vehicle transmission becomes less important than person- 
to-person transmission. Most cases are asymptomatic, which facilitates 
spread, but first exposure may occur at later ages, and so some cases will 
be symptomatic, giving rise to the appearance of small epidemics. 
Indeed, regions in which hepatitis A is solely epidemic are those in 
which there is a large susceptible population because of a low recent 
incidence, which could be caused by minimal opportunities for common- 
vehicle or person-to-person transmission. Epidemiologic data from the 
developed countries suggests that hepatitis A is primarily an epidemic 
disease, and that continual, serial transmission or common-vehicle 
transmission is prevented by public health surveillance. Because of the 
difficulty of determining the incidence of asymptomatic infection, it is 

difficult to classify regions where hepatitis A is endemic, however, many 
nations which are steadily improving their sanitation systems are 
probably passing through a phase of endemicity(47). Israel may be an 
example of such a nation. Travelers to endemic regions are at risk of 
exposure to HAV from personal contact with recently infected, albeit 
asymptomatic individuals. However, as in epidemic regions, the traveler 
is also at risk from large common-source outbreaks as occurs, for 
example, when water supplies are contaminated during accidental 
release of sewage during floods. 
Again, although the clinician may try to classify regions as 
hyperendemic, endemic and epidemic and apprise the patient of the 
risks in each region, quantitative data that would allow for an accurate 
determination of risk are not available. One might otherwise attempt to 
quantify a traveler’s risk of contracting hepatitis A in terms of his or her 
exposure to the vehicles of transmission. It is generally accepted that 
hepatitis A is spread by the fecal-oral route and therefore, that infectious 
fecal contamination of food or water or parts of the body that, unwashed, 
will have contact with the mouth, is the means of spread. 
Vehicles of Transmission 
Contamination of the water-supply is a well-recognized cause of 
epidemics, although waterborne outbreaks account for less than 1% of 
the total number of reported cases of hepatitis A(24). Although the WHO 
has recommended treating drinking water with a free chlorine residual 
of 0.3-0.5 mg/Liter for 30 minutes and isolating no viruses per 100 to 
1000 liters of drinking water, water with a free chlorine residual of 0.2- 

0.8 mg/L that was then contaminated in the distribution system and 
associated with a huge hepatitis A outbreak in India was found to have 
other viruses in concentrations of 1-7 plaque-forming units per 12-40 L 
of drinking water(24,25). Thus, even in regions where water is treated, 
the traveler is at risk when sewage contamination of the water system 
occurs, as sometimes occurs during monsoon flooding. Travelers are also 
at risk where water is not treated or chlorinated. Aside from the risks of 
obvious contamination with human waste, ponds and wells in Ghana and 
China have been shown to contain Enterovirus even though there was no 
known source. Contaminated water is also known to spread hepatitis A 
when used to clean dishes or when used in aerosol irrigation. Finally, 
recreational activites associated with contaminated lakewater have been 
implicated in one outbreak of hepatitis A(26). 
The traveler can reduce risk by not drinking or using potentially 
contaminated water. Portable chemical additives such as sodium 
hypochlorite (lOmg/L), iodine (3mg/L) and potassium permanganate 
(30mg/L) have been found to inactivate hepatitis A in contaminated 
drinking water. Boiling water will also kill the virus(2). 
Another source of hepatitis A infection is foodborne virus. This is 
generally associated with shellfish, which are often eaten uncooked and 
which, in fecally contaminated water, can concentrate the virus to an 
infectious level. Information about the risk in developing nations is 
lacking; in the U.S., however, shellfish outbreaks accounted for less than 
4% of cases in 1981(27). As the virus can withstand temperatures of 
60' C for 60 minutes, even steaming shellfish is unlikely to 

decontaminate it. Other food products, primarily uncooked, have been 
associated, if rarely, with hepatitis A outbreaks(26). 
Contaminated food-handlers are another possible source of infection. 
Contaminated foodhandlers accounted for 7% of cases in the U.S. in 
1981(27). Several states in the U.S. require restauraunt employees to 
wash their hands before returning to work after using toilet facilities, but 
it is difficult to quantitate the effect such behavior or lack thereof would 
have on the international traveler. A recent study found no increased 
incidence of hepatitis A in " adventure " travelers who lived in cheap 
accomodations or camped, as opposed to travelers who stayed in 
international level hotels, which may suggest a limited role for 
foodhandler transmission as well as for use of untreated water(28). 
Ordinary person-to-person contact is an unlikely mode of spread unless 
one person is fecally incontinent or his or her hands otherwise become 
fecally contaminated. The only healthy people who are consistently 
fecally incontinent are young children and thus, person-to-person contact 
is a frequent mode of spread in the context of day-care center outbreaks. 
Since some long-term travelers place their children in day-care centers, 
these travelers are at risk of contracting hepatitis A from their young, 
untoilet-trained children. The risk is especially pronounced since 
children, as well as adults in endemic regions are very likely to have 
asymptomatic infections. Homosexual sexual relations are considered to 
be a form of person-to-person contact that abets the transmission of 
hepatitis A. No such predilection has been demonstrated among 
travelers, however. Likewise, parenteral modes of transmission have only 
rarely been documented for hepatitis A and have not been reported in 

travelers. Thus, no recommendations about personal contact with natives 
that would substantially alter risk can be made. 
It is clear from this discussion that quantifying a traveler's risk of 
contracting hepatitis A based on exposure to the vehicles of transmission 
is difficult. A clinician can warn a patient to avoid consuming water or 
food that might be fecally contaminated, or to be wary of certain types of 
personal contact, but specific quantitative data that would allow the 
clinician to reject ISIG prophylaxis on the basis of expected forms of 
exposure during travel do not exist. 
Incidence of Hepatitis A in Travelers from Developed 
Nations During Travel to Developing Nations 
Although the importance of individual risks is difficult to quantitate, 
there have been several studies that have been able to provide some 
information on the incidence of hepatitis A in travelers from the 
developed nations. A preliminary study of American travelers in 1972 
revealed an incidence of 15 cases in 26119 (57 per 100,000) overseas 
travelers abroad for one month. This rate of approximately 70 per 
100,000 person-years is seventy times greater than the incidence 
calculated for the U.S. population in the decade 1971-1980(17). No 
correlation between infection and any aspect of type, location or duration 
of travel was provided, however(29). 
A Swedish study demonstrated a hepatitis A attack rate in 1980 of 1.4 
per 1000 and 10 per 1000 unprophylaxed travelers to Northern Africa 
and Tropical Asia or Africa, respectively(30). The attack rate for 
unprophylaxed travelers to southern Europe in 1980 was 0.17 per 1000, 

down from 0.33 per 1000 in 1965-1974, a trend attributed by the 
authors to improved socioeconomic conditions in the countries of 
southern Europe. Another Swedish study, which documents the decline 
in attack rate for travel to southern Europe from one in 3000 
unprophylaxed travelers in 1970-1972 to one in 20,000 unprophylaxed 
travelers in 1982, does not show such a decline in the risk of travel to 
Northern Africa, Tropical Africa and Asia. In 1982, the attack rates were 
one in 525, 95 and 144 unprophylaxed travelers to these regions, 
respectively(31). 
A study of unprophylaxed Danish travelers between the years 1976- 
1978 revealed a higher attack rate ( primarily of hepatitis A ) in 
individual travelers to endemic regions than in travelers in tourist 
groups(32). Attack rates, extrapolated to cases per 100,000 airline 
travelers, ranged from 0.3 in individual travelers to northern and central 
Europe to 1482 cases per 100,000 airline travelers to Central Africa. 
Other areas of risk, in decreasing order, were Central and South America 
(740.7), North Africa ( 238.1), Asia (105.2) and the Middle East, 
excepting Israel, (86.1)Attack rates were remarkably lower in group 
travelers, ranging from 32.5 and 10.3 per 100,000 travelers to North and 
Central Africa, respectively, to zero cases for most other regions. A study 
by Steffen et. al. (28) in unprophylaxed Swiss travelers, demonstrated an 
incidence of 155 cases per 100,000 traveler-months abroad but 
identified no subpopulation with specific travel characteristics ( such as 




Documentation of Effectiveness 
The effectiveness of immune serum immunoglobulin (ISIG) injections 
prior to work or travel in developing countries has been demonstrated in 
several studies few of which have been strictly controlled and double- 
blinded. Often quoted is Woodson's(33) comparison of unprophylaxed 
Protestant missionaries with routinely prophylaxed Peace Corps 
volunteers, revealing a rate of 3.0 icteric cases and 0.97 icteric or icteric 
cases per 100 person-years in the two groups, respectively. A 1969 
British study showed a seven month incidence of 0.93 and 8.5 cases per 
1000 prophylaxed and unprophylaxed relief workers, respectively(34). 
This study also showed that the effectiveness of ISIG waned after 7 
months. Likewise, a truly controlled double-blinded study of American 
soldiers in Korea revealed 20 cases of hepatitis A in approximately 
30,000 soldiers who had received ISIG within the past six months as 
opposed to 43 cases in approximately 20,000 soldiers who had not 
received ISIG, but the statistically significant differences between the two 
groups disappeared after six months(35). Since double-blind, controlled 
clinical trials of the effectiveness of ISIG prophylaxis in travelers to 
developing nations have not been performed, current CDC 





These recommendations call for the intramuscular injection of 0.02 
mL/kg ISIG for travelers who will be in developing nations for three 
months and 0.06 mL/kg every five months for extended-stay 
travelers(48). The classification of countries as "developing" is left ot the 
clinician, but extra caution is urged if patients are likely to be traveling in 
rural regions or are likely to be living in rustic accomodations. 
Aside from limitation of exposure and administration of ISIG, the CDC 
also presents the possibility of serologically testing certain people whom 
the clinician feels might be immune, in order to avoid unnecessary 
injections of ISIG. The CDC handbook does not, however, provide an 
indication on what types of people might be tested. 
Serological Screening for Immune Status of Certain Subgroups of 
the Travel Population as an Alternative to Routine ISIG Prophylaxis 
Indeed, although ISIG prophylaxis is effective, there are several 
considerations which might make a serological search for immune 
individuals a desirable alternative to routine ISIG injections. Although the 
safety of intramuscular ISIG is well-documented, there are conditions in 
which safety might be of significant concern to the patient, if 
quantitatively only of minor concern to the clinician. The cost of ISIG is 
currently low enough to make serological screening cost-effective to 
patient or provider in only a very restricted set of circumstances. 
However, there are situations in which cost of ISIG may become a greater 
impetus for serological screening. Finally, there are conditions in which 
determination of immunity would be a very convenient alternative to ISIG 
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prophylaxis, although it would be difficult to quantify the benefits gained 
by serological screening. All of these factors which might make 
serological screening for immunity a desirable alternative to routine ISIG 
prophylaxis will now be reviewed. 
Issues of Safety of ISIG Prophylaxis 
Intramuscular administration of ISIG is a safe, as well as effective 
procedure, and adverse effects are primarily anecdotal. There have been 
reports of non-fatal anaphylaxis but these are extremely rare(45). The 
concern over the possible transmission of infectious agents, particularly 
human immunodeficiency virus (HIV), has been carefully studied. Several 
patients who received ISIG containing antibodies to HIV ( collected 
before screening of donors was possible) were found subsequently to have 
positive ELISA and Western blot tests, but in all of these patients, the 
tests became negative after six months, suggesting that antibody, but not 
virus, had been transferred(36,37,38). Indeed, a study of the cold ethanol 
fractionation procedure used for ISIG production calculated the 
effectiveness of virus removal to be IX10 ^ in vitro infectious units per mL 
(IVIU/mL) for all of the steps combined(39). Since 1000 units of 
screened blood ( the usual quantity for the preparation of a batch of ISIG) 
has been calculated to have a total of 0.13 IVIU/mL, the reduction of viral 
titer of 1 O'5 could be expected to produce a very safe product, and no 
cases of persistent seroconversion to anti-HIV positivity have been 
attributed to ISIG administration(40). 
Nevertheless, particularly in those travelers who may require a second 
ISIG injection while in a developing country, where blood may not be 
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screened, where quality control is limited(41), and where needles may 
not be new, prior determination of HAV status may reduce risk by 
enabling immune individuals to avoid unnecessary injections. 
Issues of Cost of ISIG Prophylaxis 
Financial incentives for screening are not compelling but depend on 
testing philosophy and differ for patient and provider. For example, the 
cost in 1990 of 2 mL of ISIG to the patient at Yale-New Haven Hospital 
(YNHH) is $18.00. In comparison, the hospital charges $20.00 for the 
anti-HAV IgG ELISA. Hospital policy requires an anti-HAV IgM ELISA for 
all positive IgG tests, and charges the patient an additional $20.)) for this 
test. Under such circumstances, an immune patient only saves money if 
he or she has a 100% chance of immunity and will require more than two 
ISIG injections, a condition which would obtain in repeat or extended- 
stay travelers. If the hospital did not require an anti-HAV IgM test for 
obviously healthy pretravel patients with a positive anti-HAV IgG test, 
then an immune patient saves money if he or she would have required 
more than one ISIG injection. 
A provider's considerations are somewhat different, based on costs to 
YNHH. One dose of ISIG costs $2.00, the anti-HAV IgG ELISA costs $4.00 
and the anti-HAV IgM ELISA costs $10.00. If the provider insists on an 
( 
IgM test after a positive IgG test, then it saves money if a known immune 
individual would have required seven ISIG injections. If the requirement 
for the second IgM test is waived, then the provider saves money if an 
immune individual would have required two ISIG injections. Clearly, so 
long as the present ratio of ISIG administration to HAV test cost remains 
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low, cost alone is not a strong impetus for screening except in frequent 
travelers. Indeed, cost minimization strategies in the U.S. are currently 
not very sensitive to the prevalence of immunity in target populations. It 
is conceivable, however, that ISIG could become more expensive if, for 
example, supplies became limited. The recent shortage of ISIG due to 
large military requirements might provide an added incentive for 
screening. 
Suitable criteria for screening might also be important when a vaccine 
for HAV becomes available, since cost will probably initially be a greater 
issue than with ISIG prophylaxis. A recent trial of killed HAV vaccine 
produced antibodies at levels higher than those obtained with ISIG, and 
which persisted for 24 weeks. Further studies will determine if such a 
vaccine will soon be available(43). 
Issues of Convenience of ISIG Prophylaxis 
Another situation in which it might be convenient to know anti-HAV 
antibody status is in those patients who also require revaccination for 
measles before travel (ie. those vaccinated before 1980). Because ISIG 
interferes with development of active immunity to measles, the vaccine 
should not be given for at least six weeks, and preferably for three 
months after ISIG injection. Conversely, ISIG should not be given less 
than 14 days after a measles vaccine because 7-10 days is required for 
immune stimulation. Pretravel preparation might not allow for the 
maintenance of such intervals. Thus, identifying HAV immune individuals 
among those travelers also needing the measles vaccine might obviate the 
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need for untimely ISIG administration which, in turn, would require a 
repeat measles vaccine or a check of measles serology(42). 
British Studies Assessing Criteria for a Cost-Effective 
Approach to Serological Testing 
In Great Britain, which has a nationalized health service, the desire of 
the health care provider to reduce costs has led to an interest in 
determination of screening criteria. According to one British study(44), 
ISIG costs 8.00 per administration while a salivary anti-HAV IgG capture 
immunoassay costs 4.00. Thus, total cost will be quite sensitive to the 
prevalence of immunity in those tested. These investigators found a 
prevalence of immunity ranging from 27% in the >20 year old age group 
to 45% in the >50 year old age group. Prevalence in those with Asian 
surnames was 72% and was 74% in those with a history of jaundice. 
Assuming the listed costs of ISIG and the salivaiy test, considering the 
average individual lifetime requirement of ISIG to be 1.25 injections, and 
taking into account the expected age, racial composition and medical 
history of 1000 random subjects ( in whom the total HAV prevalence 
would be expected to be 26%), these authors calculated a minimization of 
cost if the following groups were tested: 1), frequent or long-stay 
travelers >30 years old 2), travelers >60 years old 3), travelers bom in 
countries of high HAV prevalence and 4), travelers with a history of 
jaundice. Costs could be maintained at current levels while at the same 
time minimizing ISIG injections in immune patients by testing patients 
with the following criteria: 1) travelers >40 years old, 2), extended - stay 
travelers, 3), travelers bom in countries of high HAV prevalence and 4), 
travelers with a history of jaundice. 
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A more recent study(45) of travelers at an inner-city travel clinic in 
London demonstrated an HAV prevalence of 42% in 104 consecutive 
travelers tested. Of these immune individuals, 61% had been born or 
raised in HAV endemic regions or had a history of jaundice (classified as 
major risk factors ) while 27% had a history of drug abuse, living in a 
squat or traveling rough, or of living with someone who had had jaundice 
( classified as minor risk factors ). Altogether, 48% of those tested who 
had minor risk factors were immune, while 100% of those with major 
risk factors were immune. However, in this population, 10% of patients 
with no risk factor were immune. 
Design of This Study to Determine Factors in Past Medical and 
Travel History Associated with Hepatitis A Immunity 
The purpose of this study was to determine which factors in the past 
medical and travel history of U.S. travelers would be associated with 
hepatitis A immunity, and to measure the overall prevalence of immunity 
in the travel clinic population. The results from this study would assist 
clinicians in deciding whom to test for immunity.As the prevalence of 
HAV immunity in the travel clinic was determined to be small, it was 
decided to do a case-control study(46). Such a study would not allow for a 
quantitative assessment of risk factors and would not provide the 
information necessary to design a cost-effective strategy for testing. 
Nevertheless, it might provide the basis for studies which could obtain 
such information if cost or other factors rendered quantitative analysis 
more clearly useful. 
Given the constraints of the extant database, only certain factors could 
be explored. It seemed probable that, as in the study of Parry et. al.(44). 
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hepatitis A immunity would be associated with greater age and with a 
history of hepatitis. Although surnames cannot be used in the U.S. to 
predict with great accuracy one’s origin, birth or upbringing in a 
developing country would likely be associated with hepatitis A immunity. 
Furthermore, previous travel to developing nations, especially without 
evidence of hepatitis A prophylaxis might be associated with hepatitis A 
immunity, since such travel would a connote a risk above that of the 
general population. Gender, on the other hand, would not be expected to 
correlate with hepatitis A immunity. Unfortunately, socioeconomic status 
of patients could not be assessed, although travel itself, and attendance at 
largely self-pay travel clinics connotes a certain socioeconomic status. 
Although these factors are not necessarily independent (eg. older 
people have had more time in which they might have traveled abroad), 
within the context of the already self-selected population that comes to a 
travel clinic, they may provide the clinician with extra impetus to 
immunologically screen. Likewise, certain aspects of patients’ travel 
intentions might prove reflective of factors in their past which are 
predictive of hepatitis A immunity. Thus, intended destination, purpose 




Patients who attended the Yale Tropical Medicine and Traveler’s 
Clinic(YTC) or the Yale University Health Services travel clinic(YHP) 
between January 1987 and September 1990 for pretravel counsel and 
immunizations were routinely tested for anti-HAV IgG antibodies in their 
serum. One of the travel clinic physicians!J.P.) claimed to have tested a 
preponderance of older patients while another physician(M.B.) reported 
testing all travel clinic patients coming for pretravel evaluation. Potential 
distinguishing factors in the subjects tested by two other travel clinic 
physicians are not known. The serological test used was the HAVAB 
Enzyme Immunoassay Kit produced by Abbott Laboratories. Patients were 
also questioned about various aspects of their past medical and travel 
history and responses were generally recorded in a standardized form. If 
time permitted, patients would return to the clinic just prior to travel 
for ISIG administration if they were found not to be immune, otherwise 
they would receive ISIG without waiting for the results of serological 
testing. 
Beginning in Spring, 1990, logbooks were reviewed manually or by 
computer search to find the unit numbers or the names of immune and 
non-immune patients. Identification of the birthdates of nearly all of 
those tested provided data on HAV prevalence in different age-groups. 
The charts of patients at the Yale Travel Clinic were checked and the 
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data concerning their past medical and travel history were collected. 
Specifically, age, gender, birthplace, current travel plans at time of visit, 
reason for travel, length of intended stay, and past history of hepatitis and 
previous travel were reviewed. Patients whose charts were incomplete 
were contacted by mail and invited to fill out a written questionnaire or 
provide responses over the telephone. Because the charts of YHP travel 
clinic patients were unavailable, mailed questionnaires were used to 
obtain information on their medical and travel history. 
Although contact with all non-immune patients was not attempted, 
subjects were chosen randomly to provide a 2:1 ratio of controls to cases. 
The names of several non-immune subjects listed on either side of those 
of immune subjects in the logbooks or computer printouts were selected. 
Because there was a greater number of non-immune subjects available for 
study, non-immune subjects with incomplete charts were not pursued, 
instead, the completed charts of other non-immune subjects would be 
selected. Collection and treatment of data proceeded according to the 
regulations of Protocol #5612 of the Human Investigation Committee of 
Yale University School of Medicine and the of the Yale University Health 
Services. 
Results were tallied and responses for various aspects of medical and 
travel history in immune and non-immune subjects were compared. 
Differences in the percentages of immune cases and non-immune 
controls with certain factors were tested for statistical significance by 
computing a chi-squared value and interpreting this with one degree of 
freedom to find the two-tailed p value. If the number of subjects included 
in a test for statistical significance was less than 150 or if the p value was 
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greater than 0.005, the Yates continuity correction was used. Odds ratios 
and the associated 95% confidence intervals were also calculated. The 
Mantel-Haenzel tests for confounding and effect modification were 




Results of Age-Prevalence Study 
HAV-Immune subjects/Total subjects in group(%) 
Age-group(years) 
0-9 10-19 20-29 30-39 40-49 50-59 60-69 >70 Total 
YHP 0/7(0) 0/1(0) 5/73(7) 10/43(23) 4/24(17) 1/9(11) 7/18(39) 7/8(88) 43/183(19) 
YTC 0/4(0) 0/20(0) 9/112(8) 13(119)11 14/79(18) 14/82(17) 14/53(26) 7/24(29) 71(493(14) 
Tot. 0/11(0) 0/21(0)14/185(8)23/162(14) 18/103(17)15/91(16) 21/71(30)14/32(44)105/676(16) 
(YHP signifies Yale University Health Services and YTC signifies Yale Tropical Medicine and 
International Traveler's Clinic) 
HAV-Immune Subjects/Total Subjects in Group(%) 













Results of Case-Control Study 
DESCRIPTION OF SUBJECTS 
Immune Non-immune 
Total 62 121 
Mean Age(range) 53(18-81) 38(17-71) 
Males(%) 27(44) 63(52) 




Subjects(% cf subjects in row) 
Age-Group(years) 0-19 20-29 30-39 40-49 50-59 60-69 >70 Total 
Immune 1(2) 3(5) 9(15) 12(19) 12(19) 18(29) 7(11) 62 
Non-immune 2(2) 35(29) 34(28) 21(17) 18(15) 10(8) 10) 121 
Total 3(2) 38(21) 43(23) 33(18) 30(16) 28(15) 8(4) 183 
GENDER 
Subjects(% of subjects in that row) 
Male Female Total 
Immune 27(44) 35(56) 62 
Non-immune 63(52) 58(48) 121 
Total 90(49) 93(51) 183 p>0.25 NS 
HISTORY OF HEPATITIS 
Subjects(% of subjects in that row) 
History of Hepatitis No History of Hepatitis Total 
Immune 20(32) 42(68) 62 
Non-immune 2(2) 119(98) 121 




PLACE OF BIRTH 
Subjects (% of subjects in that row) 
Bom in U.S. Not Bom in U.S. Total 
Immune 40(65) 22(35) 62 
Non-immune 107(88) 14(12) 121 
Total 147(80) 36(20) 183 
Breakdown of Place of Birth—Immune Subjects 





















9 (Germany-1,Italy-3, Britain-2, 
Austria-1, France-1) 
Not U.S. (not otherwise specified) 1 
Breakdown of place of birth--Non-immune subjects 





W. Europe 2 (Netherlands-1, 
Norway-1) 
Canada 1 
Not U.S. (Not otherwise specified) 6 
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PROFILE OF DESTINATIONS OF TRAVELERS 
Immune Subjects: 
Number of responses(% of subjects). Percentages will sum to greater than 
100% due to multiple responses from some subjects. 
South/Central America N. Africa Other Africa S.E. Asia Other 
11(18) 7(11) 30(48) 10(16) 11(18) 





























Philippines, Taiwan, Singapore, New Guinea, HongKong, Bali, S.E. Asia, 
Bangladesh, Pakistan, Mali, Cameroon, Morocco, Mauritania, N.W. Africa, 
Burundi, Mozambique, Liberia, Tunisia, S. Africa, Central African 




Number of Responses(% of subjects). Percentages will sum to greater 
than 100% due to multiple responses from some subjects. 
South/Central America N. Africa Other Africa S.E. Asia Other Asia 
44(36) 6(5) 54(45) 16(13) 39(32) 


















Costa Rica 2 
Sri Lanka 2 






Central Asia 2 
Mentioned once: 
Mali, Ivory Coast, Ethiopia, Zaire, Cameroon, Burundi, Zambia, N.W. 
Africa, Nigeria, Uganda, Botswana, Mauritania, Guyana, Ecuador, Mexico, 
Honduras, Argentina, S. Asia, Malaysia, Philippines, Hong Kong, Pakistan, 
Vietnam, Cambodia, Hawaii, Bhutan, Saudi Arabia, Israel 
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COMPARISON OF PROJECTED LENGTH OF TRAVEL 
Subjects(% of total of that row) 
less than or equal to 3 wks. >3wks.<lyr. >iyr. Not Mentioned Total 
Immune 37(60) 17(27) 3(5) 5(8) 62 
Non-immune 66(55) 50(41) 5(4) 0(0) 121 
Comparison of Purpose of Travel 
Responses(% of subjects in that group) 
(Percentages sum to greater than 100% because of multiple responses from some subjects) 
Business Volunteer Wk. Study Tourist Visit Relative Field Wk. Not Mentioned Sub. 
Immune 8(13) 9(15) 1(2) 32(52) 6(10) 3(5) 5(8) 62 
Non- 
immune 14(11) 23(19) 10(8) 70(57) 3(2) 2(2) 0(0) 121 
Total 22(12) 32(17) 11(6) 102(55) 9(5) 5(3) 5(3) 183 
Continent of previous developing nation travel 
Responses(% of subjects in that row) 
(% may add up to greater than 100% due to multiple responses from some subjects) 
Asia South/Central America Africa Other None 
Immune 25(40) 17(27) 23(37) 2(3) 8(13) 
Non-immune 47(39) 31(26) 29(24) 1(1) 46(38) 
Number of subjects with history of previous developing nation travel 
with history of associated immunization (not necessarily ISIG) 
Subjects(% of subjects with previous developing nation travel) 
Some evidence of previous No evidence, or denial of ' Total 
pretravel care previous pretravel care 
Immune 27(50) 27(50) 54 
Non-immune 24(32) 51(68) 75 p>.05 NS 
Evidence of previous pre-travel care included recollection of previous 
pre-travel immunizations or records of previous pre-travel visits or 
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immunizations in medical charts. In the other category were placed 
subjects who denied previous pre-travel medical care or whose medical 
charts contained no evidence of previous pre-travel visits. Patients who 
had had pre-travel visits for some but not all trips to developing nations 
were entered as having evidence of previous pre-travel medical care. 

Statistical Analysis 
I. Age-Prevalence Study in YHP and YTC Populations 
The overall prevalence of HAV immunity in the YHP and YTC 
populations was 19% and 14%, respectively. To test if this difference 
between the two populations was statistically significant, a 2x2 table 
was constructed, with clinic source as the "risk factor" and the 
number of subjects in each category entered into the appropriate cells. 
Y wp 
Ytc 







A simplified form of the equation for chi square is: 
^ (a.ti-bc^N 
(a4 b)( a-d)(cu-c)ibt-cl) 
where cells are as labelled above, and N=a+b+c+d. Thus: 
y * - —-- - I-Td 
K (3N HNq)(TM-4aa)(.^H+T-iK'K«Cl +-N22) 
At one degree of freedom (df), p(two-tailed)>0.10, signifying that 
there is a greater than 10% probability that this difference arose by 
chance. (All p values subsequently presented will be two-tailed and 
interpreted at 1 df). 
The differences in prevalences between similar age-groups in the 




Yates' continuity correction is used: 
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See Conclusions for discussion of these results. 
II. Case-Control Study 
A. Analysis of the different age-groups amongst the cases and controls. 
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The odds ratio (or, the ratio of the likelihood that immune subjects 
will have exposure to the "risk factor" to the likelihood that non- 
immune subjects will have such exposure) is determined by the 
following formula: , a j 
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The 95% Confidence Interval (95% Cl) of an odds ratio is calculated 
according to the formula: 
SSV Cl = OR 
Thus: 
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The association of increased age with immunity may be due to the 
confounding effects of the increased opportunity of older people 
already to have had previous travel to developing nations and to already 
have had hepatitis. A confounding factor must be independently 
associated with exposure (here, increased age), outcome (immunity), 
and not lie on the causal pathway from exposure to outcome. One way 
to control for confounding is by stratification of the odds ratios by 
previous travel and by previous hepatitis status, and to calculate the 
Mantel-Haenzel odds ratio. The Mantel-Haenzel(MH) analysis requires 
categorical variables and so age-groups have been stratified into >40 
year-olds and <40 year olds for this and all subsequent MH analyses. 
Assessing for the effect of previous travel: 
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These results will be discussed in the Conclusions section. The 
possible confounding effects of hepatitis in older subjects cannot be 
assessed by the MH procedure because one of the cells has a value of 
zero. However, one can check if age and hepatitis could be associated 
by comparing the average age of immune subjects with a hepatitis 
history with the average age of those without such a history. If the 
former group were much younger than the latter, then it would appear 
that hepatitis and increased age were not associated. Since the 
approximate age of both groups is approximately 53 years old, one 
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cannot rule out the possibility that increased age and hepatitis history 
are associated and therefore, may be confounding each other's 
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An attempt is made in the Conclusions section to distinguish foreign- 
bom (developed and developing countries) and U.S. bom populations 
on the basis of average age. The two-sample t-test was used to 
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An MH analysis was used to assess the confounding effects of previous 
travel to developing nations and of a hepatitis history in the association 
of immunity and foreign birth. (N.B. Small cell numbers may lessen the 
validity of some of these analyses). Effect of previous travel: 
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As the OR^ is approaching unity, a second test for statisitical 
significance must be performed using a weighted Mantel-Haenzel chi 
square calculated according to the formula: 
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D. Hepatitis History 
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For a hepatitis history, there are several possible confounding factors. 
1. Patients with a history of hepatitis may be older and for this reason 
may be more likely to be found amongst immune patients. 
2. Patients with a history of hepatitis may be more likely to have a 
history of previous travel to developing nations and for this reason may 
be more likely to be found amongst immune patients. 
3. Patients with a history of hepatitis may be more likely to have been 
born outside of the U.S. and for this reason may be more likely to be 
found amongst immune patients. 
The first two of these possibilities are not amenable to MH analysis 
because of zero subjects in some cells. However, it has been shown in 
the analysis of age that hepatitis history and age cannot be shown not 
to be associated. Applying MH analysis to the third possibility: 
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Assessment of the possible confounding effect of hepatitis could not be 
done because of zero subjects in some cells. Assessment of 
confounding effect of greater age: 
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F. Expected Destinations of travelers not assessed statistically. 
G. Expected Length of Travel (disregarding subjects with unspecified 
lengths of travel): 
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H. Purpose of Travel not assessed statistically. 
I. Subjects with a history of previous travel to developing nations who 
give a history of associated immunizations: irn^wie 
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Discussion 
Prevalence of HAV immunity was 19% and 14% in the YHP and YTC 
populations, respectively, with an increasing prevalence with 
increasing age. In the case-control aspect of the study, immune 
individuals were found more likely than non-immune individuals to be 
older, to have traveled previously, to have been bom outside of the U.S. 
or to have a history of hepatitis. Mantel-Haenzel (MH) analysis was 
performed where possible to determine the importance of 
confounding and effect-modification in the associations between these 
factors and HAV immunity. No other factors were found to be 
associated with HAV immunity. Various biases were assessed and 
considered to be of limited significance in this study. 
General Prevalence 
As the differences between the YHP and YTC populations were 
determined not to be statistically significant (p>0.05), it was decided 
to pool the results from the two groups, although incurring a Type II 
error in so doing was certainly a possibility .The prevalence of HAV 
immunity in the combined groups was 15.5%, which is lower than the 
26% and 42% reported for two British travel clinic 
populations(44,45). The prevalence was also lower than that reported 
in an American middle-class population in 1976(15,16). Because ours 
was a case-control study, however, the proportions of other subgroups 
in the two populations (such as individuals bom outside the host 
country or individuals with a history of hepatitis) could not be 
compared. Likewise, a comparison of our group with that of Szmuness 
et. al.(15) is not possible. Nevertheless, one could speculate that our 
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group came from a higher socioeconomic background than did those 
from the previous American study and from the British inner-city 
study(45).(Indeed, it is unlikely that 10% of our travel population had 
a history of drug abuse, living in a squat or traveling rough, as was the 
case in that British study) .Another possible explanation for a lower 
prevalence of HAV immunity in our study could be a reduced 
prevalence in the population as a whole as compared with those in 
Britain or those in the U.S. in the 1970's. Finally, it should be 
remarked that in the study of Parry et. al.(44), a conscious effort was 
made to test a population likely to have a higher prevalence of HAV 
immunity, though the degree to which this overestimated the 
prevalence of the population as a whole is not clear. It is interesting to 
note that very little work on the prevalence of HAV immunity in the 
U.S. has been done since the 1970's, although it is not certain that 
revelation of any changes would be very useful since the incidence of 
hepatitis A is currently very low and since outbreaks usually have well- 
recognized sources. 
Age Factor and Hepatitis A Immunity 
The increasing prevalence with increasing age was expected. Older 
patients have had more time in which to be exposed to HAV and to 
develop lifelong immunity. Furthermore, seroepidemiologic data from 
the developed nations suggest that it is within the past 50-75 years 
that hygienic standards progressed to a point capable of reducing 
incidence of hepatitis A, and so, older patients have lived in time 
periods when incidence was higher than it is now(22,23). 
An analysis of the age profiles of the case-control study groups 
reflects the increased prevalence with increased age by demonstrating 
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a greater likelihood that immune individuals will be older than a 
certain age than their non-immune controls will be. The only age cut¬ 
off where such a likelihood is not statistically significant is 20 years 
old. The odds ratios do not follow an explicable pattern but statistical 
significance is greatest for the age cut-off of 60 years where it is seen 
that immune individuals are 6.8 times more likely to be over 60 years 
old than are their non-immune counterparts. 
The possible confounding effect of previous travel to developing 
nations and of a hepatitis history was assessed because older patients 
may have had more time to experience either of these potential 
factors than younger patients will have had, and these factors may be 
independently associated with immunity. Stratifying the >40 and <40 
year-old age-groups by presence or absence of previous travel did not 
reduce the MH odds ratio, and so the greater odds of older people 
being found among immune individuals is not due to the greater 
possibility that they will have traveled previously. On the other hand, 
there is striking effect modification, wherein it is seen that immune 
subjects with a history of previous travel have a less increased 
likelihood(OR=4.5) to be found to be older than immune subjects 
without such a history(OR=l 1.9), suggesting that age and previous 
travel are independently associated with immunity. (Ie. if one factor 
accounts for a subject's immunity, then the other does not). 
Alternatively, if one considers odds ratios to be equivalent to risk 
ratios (which can be done for low-prevalence outcomes), the presence 
of previous travel reduces the relative risk of older age "causing" 
immunity. What this means biologically is not clear, however, the 
presence of effect modification informs the clinician that increased 
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age will be a more important predictive factor for immunity in patients 
without a history of previous travel to developing nations than in those 
with such a history. The possibility that an older person will have had 
more time to contract hepatitis and that this accounts for the 
increased odds of finding older people among immunes could not be 
checked by the MH procedure, and calculation of average ages 
demonstrated that an association of age and hepatitis cannot be ruled 
out. ( Note that such an association between age and symptomatic 
hepatitis presumably accounts for only part of the increased 
prevalence of immunity in older people, as one expects many of these 
older people to have developed immunity when hepatitis A was an 
endemic disease and therefore, more likely to express itself in 
asymptomatic form. Indeed, to be a true confounder, cases of 
symptomatic hepatitis cannot be a result of increased age). 
Gender Factor and Hepatitis A Immunity 
Gender was shown not to bear a statistically significant relationship 
to immunity. Although immune individuals were only 0.71 times as 
likely to be males as were their non-immune counterparts, the chi 
square value demonstrated that there was a greater than 25% 
probability that this discrepancy had occurred by chance. 
Furthermore, the 95% Cl of the odds ratio (0.38 to 1.32) includes 1.0, 
which implies no added or reduced likelihood of immune individuals 
being male. It was not expected that immunity would be associated 




Place of Birth and Hepatitis A Immunity 
Conversely, immune individuals were found to have a statistically 
significant 4.2 times greater probability of being born outside the U.S. 
than were non-immune individuals. This would imply that individuals 
bom outside of the U.S. have a higher prevalence of immunity to 
hepatitis A, as was also suggested by the data of Szmuness et. al.(15). 
The mean ages of U.S. bom and foreign-bom immune subjects were 
57.3 and 45.5, respectively(p<.005) which suggests that age and 
foreign birth are independently associated with immunity. (Such a 
discrepancy in mean ages(38.4 years) between foreign and U.S.-bom 
non-immune subjects did not exist, further supporting the 
independence of age and place of birth in determining immunity). An 
increased prevalence might be expected in those born in developing 
countries as well as in older patients bom in countries which had a 
higher incidence than the U.S. years ago, but which may be considered 
developed countries now and which have a low incidence currently. 
Approximately one-half of the foreign-born individuals were from the 
developing countries while the rest were from western Europe. Their 
mean ages were 38.5 and 55.6 years, respectively,(p<.001), which 
would seem to support such a distinction. (On the other hand, a 
discrepancy also existed between the mean ages of foreign-bom non- 
immune subjects from developing and developed countries(27 and 36 
years, respectively),although statistical significance was much 
less(p<.05) and many foreign-bom subjects had not provided a country 
of birth). 
The possibility that foreign-bom individuals were more likely to have 
previously traveled to developing nations, or to have had hepatitis, and 
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that either of these possibilities may have accounted for the increased 
odds of finding foreign-bom subjects among immunes was subjected to 
MH analysis. Indeed, because more foreign-bom individuals were 
likely to have traveled previously, the adjusted OR^of 3.6 was lower 
than the crude OR of 4.2. Nevertheless, one notes an effect- 
modification wherein immune subjects with a history of previous travel 
have a less-increased likelihood of being found to be foreign- 
bom(OR=3.4) than those without previous travel(OR=4.8), suggesting 
that although foreign-bom individuals are more likely to have had 
foreign travel, this does not account for their immunity. A hepatitis 
history is found not to be a confounding factor(OR^H=4.2). Moreover, 
the effect modification shows that a hepatitis history and foreign birth 
are unlikely both to account for one's immunity. Again, considering 
odds ratios to be equivalent to risk ratios, one could conclude that 
foreign birth is a more useful predictive factor for immunity in those 
patients without a history of hepatitis or of previous developing nation 
travel than in those with such a history. 
Hepatitis History and Hepatitis A Immunity 
Immune individuals had 28.3 greater odds of having a history of 
hepatitis than did non-immune individuals. It would be expected that a 
past episode of hepatitis would be correlated with HAV immunity even 
if, as noted in previous studies(15,16), only 3-5% of HAV immune 
individuals will give a history of hepatitis. This study suggests that 32% 
of immune individuals can give such a history. This may signify that 
travel patients develop hepatitis A in a context in which it is more 
likely to be symptomatic or diagnosed, a possibility that would seem 
consistent with the expected higher socioeconomic status of travelers. 
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On the other hand, some of the patients with hepatitis were young and 
were born outside of the U.S. and so may have contracted hepatitis A 
in an endemic region. 
It has been shown that a history of hepatitis and of increased age 
may be associated with each other, although the nature of this 
association is not demonstrable with these data. The possible 
association of previous travel and hepatitis history could not be 
assessed because of cells with zero subjects. The possible confounding 
effect of foreign-birth(associated with, but not causing a hepatitis 
history, and associated with immunity) was shown to be significant, as 
the ORof 19.6 is markedly reduced from the crude OR of 28.3. 
Nevertheless, a history of hepatitis is still a very important factor 
associated with immunity and could be considered to be highly 
predictive of immunity, particularly in U.S. bom patients. 
Previous Travel and Hepatitis A Immunity 
Previous travel to developing countries was expected to have some 
correlation with immunity.Even prophylaxed travelers from the U.S. 
have, according to the data of Woodson(33) and Conrad and 
Lemon(35), a 7-100-fold greater incidence of hepatitis A than 
individuals in the U.S.(17). The incidence is even greater for 
unprophylaxed travelers. Two of the twenty immune individuals with a 
history of hepatitis in this study had developed hepatitis during 
previous travel, although one of these cases occurred in France from 
eating raw seafood. Since most cases of travel hepatitis would occur in 
adults and thus, be symptomatic, it is surprising that despite the large 
percentage of immune travelers who had traveled to developing 
countries, only one of them could attribute immunity to that factor. 
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Nevertheless, immune subjects had a 4.1 times greater probability of 
previous travel to developing nations than did non-immune subjects. 
An MH analysis for confounding of the association of immunity and 
previous travel by hepatitis history was not done due to zero values in 
some cells. One might doubt the value of such an analysis anyways, 
because one would expect that most immunity secondary to previous 
travel would arise from symptomatic cases of hepatitis A (since most 
travelers are adults). If this were the case, a hepatitis history would lie 
along the causal path from exposure(travel) to outcome (immunity) 
and thus not fulfill the criteria for a confounding factor. Greater age is 
shown not to confound the association of previous travel with 
immunity(OR^ =4.0 ORcrj=4.1), although a history of previous travel 
to developing nations is of greater predictive value in younger 
patients(OR=8.3) than in older patients. Foreign birth does confound, 
to some extent, the association of immunity with previous travel (OR 
=3.6) although the MH chi square and the 95% Cl of OR^ suggests 
that the association is still statistically significant. One notes some 
effect modification; thus, previous travel is of greater predictive value 
for immunity in U.S. bom individuals than it is in foreign-bom 
individuals. 
Previous Pretravel Care and Hepatitis A Immunity 
An attempt to find a correlation between a lack of previous pre- 
travel care and immunity failed to achieve statisitical significance. 
Since very few charts and very few recollections provided specific 
information on presence or absence of ISIG prophylaxis before some 
or all trips abroad, presumptive evidence had to be considered. For 
example, immunizations against yellow fever and cholera, or previous 
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use of antimalarials was considered as evidence of pre-travel medical 
care during which ISIG may have been administered. The absence of 
any such information, which was taken as evidence of no pre-travel 
medical care, may have been due instead, simply to omission of such 
data. Thus, the presumptive nature of the data may very well account 
for the inconclusiveness of this part of the study. 
Destinations of Travel in Travel Clinic Patients 
The destinations of immune and non-immune individuals were not 
subjected to statistical analysis because no trend was readily apparent 
in the destinations of the two groups. Furthermore, it would have been 
difficult to explain how any trend would reflect a greater probability of 
being immune. The destinations, however, represent a fair distribution 
in the areas shown to be of increased hepatitis A risk for travelers ie.. 
Tropical Africa, South and Central America, Asia and North Africa. The 
data on attack rates do not enable one to make very refined estimates 
of risk for individual travelers. For example, attack rates are probably 
lower in the more developed areas of Southeast Asia such as Thailand, 
Hong Kong and Taiwan than they are in China, but the attack rate is 
only estimable for travel to Asia as a whole. 
Purpose of Travel in Travel Clinic Patients 
Likewise, purpose of travel probably influences one's risk for 
contracting hepatitis A , but data are not available for quantifying how 
it might do so. Intuitively, one would expect that business and study 
which took place in urban centers would pose the lowest risk while 
field research and volunteer work might pose the greatest risk. 
Traveling as a tourist probably presents a wide range of risks; whereas 
the Steffen study(28) did not show that the "roughness" of travel 
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affected incidence, the Danish study(32) demonstrated much higher 
attack rates in individual as opposed to group travelers. Five out of six 
immune individulals visiting relatives had been bom in the developing 
country they were visiting, whereas none of the non-immune travelers 
visiting relatives were bom outside of the U.S. This suggests that most 
travelers visiting relatives in a developing nation in which they 
themselves were bom would probably already be immune. Presumably, 
visits to relatives could pose substantial risks to non-immune subjects 
since such visits might involve significant personal contact and living 
in households with very young, untoilet-trained children. 
Assessment of Biases 
Although nearly all patients entering the travel clinic were tested, 
the study was potentially subject to several types of biases. 
Informational bias is possible because conceivably, patients more likely 
to be immune may have experienced differential recall of past history, 
as they may have had a more sophisiticated knowledge of travel- 
related diseases since they were older, more likely to have been 
foreign-born and were more likely to have traveled previously. 
Observer bias was avoided either by questioning patients before test 
results were known, or by asking the same specific questions of both 
immune and non-immune individuals. Confounding bias results from 
the potential associations between the factors associated with 
immunity independent of their association with immunity. Mantel 
Haenzel (MH) analysis where possible and appropriate demonstrates 
some cases of confounding but in no cases did confounding remove all 
statistical significance from given odds ratios. Furthermore, the 
revelation of effect modification by subgroup analysis demonstrated 
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that some factors are (if odds ratios are interpreted as risk ratios) 
more predictive of immunity in the absence of other factors. This is in 
contrast to synergism, which might have occurred, if having multiple 
"risk factors" increased a given subject's chance of being immune. 
The pervasive problem of selection bias is only somewhat 
problematic. Patients at travel clinics are clearly a self-selected 
population amongst travelers. Nevertheless, this study only concerns 
itself with patients who, for various reasons, refer themselves to travel 
clinics before travel to developing nations. The degree of selection bias 
introduced by the preponderance of older patients in the subjects 
tested by physician J.P. is not clear. Nevertheless, the effect of such a 
bias would be a potential underestimation of the association of 
increased age with immunity, an association already demonstrated in 
the age-prevalence portion of the study. The difference in follow-up of 
immune and non-immune patients was felt not to introduce a 
significant amount of selection bias since there were no apparent 
differences between non-immune individuals with complete charts 




This study demonstrated a directly age-related increase in the 
prevalence of hepatitis A immunity in two university-affiliated travel 
clinic populations, with an overall prevalence of 15.5%. In the case- 
control aspect of the study, it was found that immune individuals were 
older, and were more likely to have been bom outside of the U.S., to 
have a history of hepatitis and to have traveled to developing nations 
than were their non-immune controls. Conversely, gender, destination 
of travel, purpose of travel and evidence of previous pretravel medical 
care could not be shown to bear any relationship with HAV immunity. 
Confounding and selection biases were found not to significantly 
affect the results of this study. On the other hand, MH analyses 
revealed several cases of effect-modification. Thus, increased age was 
shown to have a stronger association with HAV immunity in the 
absence of a concurrent history of previous developing nation travel. 
Likewise, foreign birth was associated more strongly with HAV 
, immunity in younger patients than in older patients, and in patients 
without a history of hepatitis or of previous travel to developing 
nations. Finally, a history of hepatitis was found to have a stronger 
association with HAV immunity in U.S.-bom individuals than in 
foreign-bom individuals. 
As has been discussed, travelers to developing nations are at risk for 
developing hepatitis A, which can be a serious disease. Classification of 
patterns of infection and avoidance of vehicles of transmission are not 




recommends prophylaxis with ISIG. Although this procedure is safe, 
effective and relatively cheap, it must be repeated every four to six 
months for repeat or extended-stay travelers. Furthermore, conditions 
exist in which the safety, cost and convenience may be of concern to 
travelers, if not always to clinicians. Thus, serological screening for 
pre-existing hepatitis A immunity may be an alternative to routine ISIG 
prophylaxis, since immune individuals do not need ISIG. 
This study has identified factors that may be associated with 
hepatitis A immunity in patients at U.S. travel clinics in general. The 
clinician can determine if a patient has any of these factors in a 
routine medical interview. Patients with one or some of these factors 
can be counselled on the possibility of serological determination of 
immune status instead of routine ISIG prophylaxis before travel to 
developing nations. Although this study does not provide the data 
necessary to design a cost-effective strategy for screening, it does, 
within the context of clinical judgment, allow the clinician to make an 
informed choice about whom to test. The patient who is found to be 
immune can thereby avoid unnecessary injections which are painful, 
and which may be associated with issues regarding safety, cost and 
convenience, which, though difficult to quantify, may be of 
considerable concern to the patient. 
Furthermore, this study furnishes the groundwork for future 
research which could provide data necessary for the design of a cost- 
effective screening program. Populations with the factors identified in 
this study could be tested, to determine the prevalence of hepatitis A 
immunity in these groups, as compared with the prevalence in the 
general travel clinic population. Combined with potentially changing 
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concerns of cost and safety, these data would allow for the design of a 
cost-effective screening program. 
In the interim, however, it is hoped that this study will enable some 
patients to avoid unnecessary injections of ISIG. Although the benefits 
derived thereby have been difficult to quantify, the opportunity to 
spare patients unnecessary pain, concern and inconvenience is a 
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